Table 2.
Frequency of reporting symptoms of respiratory tract infection last week by characteristics of 6414 middle-aged and elderly adults taking part in the Tromsø 6 survey
| |
Symptoms of RTI last week |
Days since start of symptoms |
Symptoms of RTI last week that started within the previous 7 days |
|||||
|---|---|---|---|---|---|---|---|---|
| n | % | p-value | median | p-value | n | % | p-value | |
|
All (n = 6414) |
798 |
12 |
|
8 |
|
340 |
5.3 |
|
|
Gender | ||||||||
| Male (n = 2754) |
350 |
13 |
0.6 |
8 |
0.6 |
149 |
5.4 |
0.7 |
| Female (n = 3660) |
448 |
12 |
|
8 |
|
191 |
5.2 |
|
|
Age | ||||||||
| <55 years (n = 1059) |
141 |
13 |
0.001# |
7 |
0.03£ |
79 |
7.5 |
<0.001# |
| 55-64 years (n = 2656) |
354 |
13 |
|
9 |
|
138 |
5.2 |
|
| 65-74 years (n = 1752) |
230 |
13 |
|
9 |
|
217 |
5.5 |
|
| ≥ 75 Years (n = 947) |
947 |
8 |
|
14 |
|
123 |
2.7 |
|
|
Smoking (n = 6323) | ||||||||
| Current (n = 1158) |
214 |
19 |
<0.001# |
11 |
0.01£ |
76 |
6.6 |
0.7 |
| Previous (n = 2955) |
334 |
11 |
|
8 |
|
132 |
4.5 |
|
| Never (n = 2210) |
240 |
11 |
|
7 |
|
126 |
5.7 |
|
|
Season | ||||||||
| Winter (November-April) (n = 3128) |
425 |
14 |
0.007 |
9 |
0.2 |
175 |
5.6 |
0.3 |
| Summer (May-October) (n = 3286) |
373 |
11 |
|
8 |
|
165 |
5.0 |
|
|
Self-reported disease& | ||||||||
| Asthma, not COPD (n = 457) |
69 |
15 |
0.07 |
11 |
0.5 |
28 |
6.1 |
0.4 |
| COPD, not asthma (n = 172) |
25 |
15 |
0.4 |
14 |
0.09 |
6 |
3.5 |
0.3 |
| Both asthma and COPD (n = 141) |
22 |
16 |
0.3 |
12 |
0.5 |
9 |
6.4 |
0.6 |
| Neither asthma nor COPD (n = 5578) |
679 |
12 |
0.09 |
8 |
0.1 |
296 |
5.3 |
1.0 |
| Cardiovascular disease (n = 1154) |
134 |
12 |
0.3 |
12 |
0.02 |
47 |
4.1 |
0.04 |
|
Self-rated health (n = 6353) | ||||||||
| Good/exellent (n = 3949) |
449 |
11 |
0.001# |
8 |
0.01£ |
207 |
5.2 |
0.9 |
| Neither good nor bad (n = 2057) |
288 |
14 |
|
10 |
|
109 |
5.3 |
|
| Bad/very bad (n = 347) |
53 |
15 |
|
14 |
|
19 |
5.5 |
|
|
Lung function (n = 6305) | ||||||||
| Normal/restrictive (n = 4881) |
567 |
12 |
<0.001# |
8 |
<0.001£ |
267 |
5.5 |
0.2# |
| GOLD 1 (n = 643) |
80 |
12 |
|
11 |
|
26 |
4.0 |
|
| GOLD 2–4 (n = 781) |
134 |
17 |
|
13 |
|
31 |
4.6 |
|
|
Self-reported asthma or COPD and lung function combined (n = 6305) & | ||||||||
| Asthma or COPD not reported, FEV1/FVC ≥ 0.7 (n = 4436) |
511 |
12 |
0.001 |
8 |
0.009 |
235 |
5.3 |
0.7 |
| Asthma or COPD reported, FEV1/FVC ≥ 0.7 (n = 445) |
56 |
13 |
0.9 |
7 |
0.09 |
32 |
7.2 |
0.05 |
| Asthma or COPD reported, FEV1/FVC <0.7 (n = 380) |
61 |
16 |
0.03 |
14 |
<0.001 |
11 |
2.9 |
0.04 |
| Asthma or COPD not reported but GOLD 1 spirometry (n = 559) |
69 |
12 |
1.0 |
9 |
0.9 |
25 |
4.5 |
0.4 |
| but GOLD 2–4 spirometry (n = 485) | 84 | 17 | 0.001 | 12 | 0.04 | 26 | 5.4 | 0.9 |
#Chi-square linear trend.
&Subject with and without the condition are compared.
£ Jonckheere-Terpstra test.